Relevant bibliographies by topics / Breast Cancer South Australia

Academic literature on the topic 'Breast Cancer South Australia'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Breast Cancer South Australia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Breast Cancer South Australia"

1

DE IESO, Paul B., Andrew E. POTTER, Hien LE, Colin LUKE, and Raghavendra V. GOWDA. "Male breast cancer: A 30-year experience in South Australia." Asia-Pacific Journal of Clinical Oncology 8, no. 2 (February 20, 2012): 187–93. http://dx.doi.org/10.1111/j.1743-7563.2011.01492.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bilinski, Kellie, Karen Byth, and John Boyages. "Association between Latitude and Breast Cancer Incidence in Mainland Australian Women." Journal of Cancer Research 2014 (December 9, 2014): 1–9. http://dx.doi.org/10.1155/2014/149865.

Full text
Abstract:
Aim. To investigate whether breast cancer incidence increases with increasing latitude in mainland Australian women. Methods. A cross-sectional study of female breast cancer and cutaneous melanoma incidence 2002–2006 by 5-year age group and local government area. Latitude, Accessibility/Remoteness Index of Australia (ARIA), and Index of Relative Socioeconomic Disadvantage (IRSD) were assigned to local government areas. Latitude was grouped into bands (≤27°S; >27–30°S; >30–33°S; >33–36°S, and >36°S), and IRSD was divided into quintiles and ARIA into four categories. Breast cancer rates were age standardized using the direct method. The joint effects of latitude, age, IRSD, and ARIA on incidence of breast cancer and cutaneous melanoma were assessed using multiple logistic regressions. Results. At latitudes south of 30°S, rates of breast cancer were over double that north of 27°S (76.4 versus 160.2–176.5). Age-adjusted odds ratios of breast cancer were increased in all latitudes south of 30°S compared with north of 27°S within each IRSD and ARIA category (all P<0.001). After adjusting for age, IRSD, and ARIA, the odds ratio of breast cancer south of 30°S was 1.92 (95% CI 1.84–2.09; P<0.001), whereas cutaneous melanoma was 0.65 (95% CI 0.61–0.68; P<0.001) times north of 30°S. Discussion. Increasing latitude is positively associated with breast cancer and negatively associated with cutaneous melanoma incidence. These findings support suggestions that increased risk of breast cancer might be explained by lower ultraviolet radiation-induced vitamin D synthesis.
APA, Harvard, Vancouver, ISO, and other styles
3

Taylor, Richard, Stephen Morrell, Jane Estoesta, and Ann Brassil. "Mammography Screening and Breast Cancer Mortality in New South Wales, Australia." Cancer Causes & Control 15, no. 6 (August 2004): 543–50. http://dx.doi.org/10.1023/b:caco.0000036153.95908.f2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tallis, G. M., and T. J. O’Neill. "Evaluation of the impact of breast cancer screening in South Australia." Internal Medicine Journal 39, no. 3 (March 2009): 174–78. http://dx.doi.org/10.1111/j.1445-5994.2008.01886.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Beckmann, Kerri Rose, David Murray Roder, Janet Esther Hiller, Gelareh Farshid, and John William Lynch. "Influence of Mammographic Screening on Breast Cancer Incidence Trends in South Australia." Asian Pacific Journal of Cancer Prevention 15, no. 7 (April 1, 2014): 3105–12. http://dx.doi.org/10.7314/apjcp.2014.15.7.3105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Chiu, Clayton, Stephen Morrell, Andrew Page, Mary Rickard, Ann Brassil, and Richard Taylor. "Population-based Mammography Screening and Breast Cancer Incidence in New South Wales, Australia." Cancer Causes & Control 17, no. 2 (March 2006): 153–60. http://dx.doi.org/10.1007/s10552-005-2368-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tallis, G. M., P. Leppard, and T. J. O'Neill. "The effect on survival of early detection of breast cancer in South Australia." Model Assisted Statistics and Applications 1, no. 2 (July 14, 2006): 115–23. http://dx.doi.org/10.3233/mas-2005-1208.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lee, C. K., L. Browne, P. Bastick, and W. Liauw. "Women from non-English speaking backgrounds living in Australia present with later stage breast cancer: A population study." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 17043. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.17043.

Full text
Abstract:
17043 Background: Ethnicity may influence both the incidence and prognosis of breast cancer. We have conducted an analysis to determine if women from non-English speaking backgrounds (NESB) living in New South Wales (NSW), Australia, present with later stage breast cancer compared to women from English speaking backgrounds (ESB); and to determine whether there is an impact on their survival. Methods: Data from the NSW Cancer Registry (1980 to 2004) was used to identify women with their first presentation of breast cancer. Stage of breast cancer was classified as early (insitu or localized) versus late (regional nodal or distant metastatic spread) according to registry definitions. Country of birth was used as a surrogate for language status. Stage at diagnosis was compared between ESB versus NESB women. Logistic regression was used to determine the odds of late stage disease and Cox regression to determine survival outcomes Results: 60,676 of 75,583 cases were considered suitable for analysis. Of these 16.64% were NESB. Accounting for potential confounding variables, NESB women were more likely to have late stage disease than ESB women (OR= 1.12; 95% CI, 1.07 to 1.17). Analysis by geographical region of birth revealed women born in Middle Eastern region were most likely to have late stage disease at presentation (OR 1.41; 95% CI, 1.25 to 1.60). In multivariable analysis of all-cause mortality NESB women had a superior overall survival (HR 0.90; 95% CI 0.87 to 0.94) compared to ESB women, however, there was no difference in breast cancer specific survival between these groups by univariate analysis (logrank p=0.46). Conclusions: In New South Wales, Australia, NESB women have a delayed presentation with breast cancer as indicted by more advanced stage. However, stage-adjusted, breast cancer specific survival in NESB women is similar to the ESB women. Further studies are required to determine the reasons for delayed detection for NESB women. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
9

Butow, Phyllis Noemi, Lynley Aldridge, Melanie Bell, Ming Sze, Maurice Eisenbruch, Madeleine King, Michael Jefford, Penelope Schofield, Priya Duggal-Beri, and David Goldstein. "Cancer survivorship outcomes in immigrants." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 6111. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.6111.

Full text
Abstract:
6111 Background: Immigration is increasing world-wide. Cancer survivorship is now recognised as a period of difficult adjustment for all patients, and possibly more so for immigrants. We explored disparities in quality of life outcomes for immigrant (IM) versus Anglo-Australian (AA) cancer survivors. Methods: In a cross-sectional design, cancer survivors were recruited through the New South Wales, Queensland and Victorian Cancer Registries in Australia. IM participants, their parents and grandparents were born in a country where Chinese, Greek, or Arabic is spoken and spoke one of those languages. AAs were born in Australia and spoke English. All were diagnosed with cancer 1-3 years previously. Questionnaires (completed in preferred language) included the Hospital Anxiety and Depression Scale (anxiety/ depression), FACT-G (quality of life) and Supportive Care Needs Survey (unmet needs). Outcomes were compared between AA and IM groups in adjusted regression models that included age, gender, socio-economic status, education, marital status, religion, time since diagnosis and cancer type (prostate, colorectal, breast and other). Results: There were 599 participants (response rate 41%). Consent was unrelated to demographic and disease variables. AA and IM groups were similar except that immigrants had higher proportions in the low and highly educated groups (p < 0.0001), and higher socioeconomic status (p = 0.0003). In adjusted analyses (see table), IMs had clinically significant higher depression (possible range 0-21), greater unmet information and physical needs, and lower quality of life than AAs. The possible range for the latter three is 0-100. Conclusions: Immigrants experience poorer outcomes in cancer survivorship, even after adjusting for socio-economic, demographic and disease differences. Interventions are required to improve their adjustment after cancer. Results highlight areas of unmet need that might be better addressed by the health system (particularly with regard to provision of information and support. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
10

Yu, Xue Qin, David Goldsbury, Sarsha Yap, Mei Ling Yap, and Dianne L. O'Connell. "Contributions of prognostic factors to socioeconomic disparities in cancer survival: protocol for analysis of a cohort with linked data." BMJ Open 9, no. 8 (August 2019): e030248. http://dx.doi.org/10.1136/bmjopen-2019-030248.

Full text
Abstract:
IntroductionSocioeconomic disparities in cancer survival have been reported in many developed countries, including Australia. Although some international studies have investigated the determinants of these socioeconomic disparities, most previous Australian studies have been descriptive, as only limited relevant data are generally available. Here, we describe a protocol for a study to use data from a large-scale Australian cohort linked with several other health-related databases to investigate several groups of factors associated with socioeconomic disparities in cancer survival in New South Wales (NSW), Australia, and quantify their contributions to the survival disparities.Methods and analysisThe Sax Institute’s 45 and Up Study participants completed a baseline questionnaire during 2006–2009. Those who were subsequently diagnosed with cancer of the colon, rectum, lung or female breast will be included. This study sample will be identified by linkage with NSW Cancer Registry data for 2006–2013, and their vital status will be determined by linking with cause of death records up to 31 December 2015. The study cohort will be divided into four groups based on each of the individual education level and an area-based socioeconomic measure. The treatment received will be obtained through linking with hospital records and Medicare and pharmaceutical claims data. Cox proportional hazards models will be fitted sequentially to estimate the percentage contributions to overall socioeconomic survival disparities of patient factors, tumour and diagnosis factors, and treatment variables.Ethics and disseminationThis research is covered by ethical approval from the NSW Population and Health Services Research Ethics Committee. Results of the study will be disseminated to different interest groups and organisations through scientific conferences, social media and peer-reviewed articles.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Breast Cancer South Australia"

1

Cheok, Frida. "Participation in mammographic screenings in South Australia /." Title page, contents and abstract only, 1998. http://web4.library.adelaide.edu.au/theses/09PH/09phc51843.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Agenbag, Gloudi. "Molecular genetic analysis of familial breast cancer in South Africa." Thesis, Link to the online version, 2005. http://hdl.handle.net/10019/953.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Macharper, Anthony G. "Survival from cancer and socio-economic status in South Australia /." Title page, table of contents and abstract only, 1992. http://web4.library.adelaide.edu.au/theses/09MPM/09mpmm149.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Daries, Valdiela. "The profile of breast cancer among patients attending a Breast Clinic in Cape Town, South Africa." Master's thesis, University of Cape Town, 2013. http://hdl.handle.net/11427/6033.

Full text
Abstract:
Includes abstract.
Includes bibliographical references.
Breast cancer is the leading cancer among women in South Africa (SA). Studies conducted in developing countries have shown that the majority of women present with advanced stage breast cancer at diagnosis. There is a gap in terms of recent data on the profile of breast cancer patients in SA. The purpose of the study was to obtain recent data with regards to the sociodemographic, clinical and risk factor profile of breast cancer in patients who presented at a Breast Clinic linked to a tertiary public hospital in the Western Cape in order to underpin the development of strategies for earlier detection and diagnosis of breast cancer. A cross-sectional descriptive medical record review was conducted. The studypopulation included all newly diagnosed patients with histological or cytological confirmedbreast cancer who presented at the Breast Clinic during the period 01 January 2009 to 31December 2010. All patients with a previous diagnosis of breast cancer were excluded. Data onthe socio-demographic, clinical and risk factor profile of breast cancer patients were collectedusing a standardised data capture sheet. Data was entered using Epidata version 3.1 and analysedusing Stata Statistical package version 12.After calculation of initial descriptive analysis for the whole sample, male subjects wereexcluded and further analysis was restricted to 585 female subjects. Stage at presentation wascategorised as “early stage” (stage 0, I, IIA, IIB) and “late stage” (stage IIIA, IIIB, IIIC, IV). Crude associations of potential predictors with stage at presentation were tested using Wilcoxon rank-sum tests for medians and Chi-square tests and Fischer Exact tests for proportions. Logistic regression was used to create a model with stage at presentation as dependent variable. Age and racial group were introduced in the model as possible confounders. Based on literature findings other variables present in the dataset were considered as potential predictors of stage at presentation (namely place of residence, employment status, medical aid status, family history of breast cancer, menopausal status, parity, having ever smoked or used alcohol, clinical signs of breast cancer as well as duration of symptoms) and introduced in the model if their bivariate association with the outcome (adjusted for age and race) was statistically significant. A significance level of p <; 0.15 was used. The only variable showing a significant association according to this criterion was the ordinal variable duration of symptoms. The final logistic regression model, therefore, included stage at presentation as the dependent variable and age, racial group and symptom duration as predictors.
APA, Harvard, Vancouver, ISO, and other styles
5

Moore, Simon Reading. "Oral cancer in South Australia : a twenty year study 1977-1996." Title page, table of contents and precis only, 1999. http://web4.library.adelaide.edu.au/theses/09DM/09dmm824.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kramer, Nicole. "Prevalence of shoulder morbidity after treatment for breast cancer in South Africa." Master's thesis, University of Cape Town, 2018. http://hdl.handle.net/11427/27973.

Full text
Abstract:
Introduction: Breast cancer is the most frequently diagnosed cancer and leading cause of cancer death among women and represents a considerable public health burden in South Africa and other low-middle income countries. Breast cancer management comprises single or combination treatment including surgery, radiotherapy and chemotherapy. Short and long-term complications of these treatments include shoulder morbidities such as pain, decreased range of motion, tightness, weakness, pain, numbness and lymphoedema, and may be present for up to 6 years post-surgery. An understanding of baseline demographic and clinical risk factors can guide rehabilitation and management strategies for high risk patients. Materials and Methods: This study was a cross-sectional analysis of the prevalence of shoulder pain and dysfunction in women attending their post-treatment annual follow up visit for unilateral breast carcinoma. The aim of this study was to quantify the burden of shoulder pain and disability in a tertiary academic hospital in Cape Town, South Africa, and identify potential risk factors for the development of shoulder morbidity. The primary objective of this study was to determine the prevalence of shoulder morbidity and the secondary objective was to evaluate associations between shoulder morbidity and risk factors such as treatment protocol or baseline demographics. Results: The majority of patients were of mixed ancestry, had their left side affected, received ALND and had undergone Modified Radical Mastectomy. The mean age was 60 years with a mean follow-up since surgery of 6 years. Three-quarters of patients reported a presence of pain or disability; 9% experienced severe pain and disability. Multivariable ordinal logistic regression analysis identified race, side, axillary surgery, chemotherapy and age as significant predictors of pain, and chemotherapy a significant predictor of disability. Discussion: The substantial burden of shoulder morbidity in this population represents a significant public health burden. The use of identified clinical and demographic characteristics may guide in the development of survivorship programmes incorporating surveillance and management of these high risk patients.
APA, Harvard, Vancouver, ISO, and other styles
7

Sagoo, Parminder. "Experiences of South Asian women with breast cancer : coping via 'strength through connection'." Thesis, University of East London, 2010. http://roar.uel.ac.uk/1882/.

Full text
Abstract:
The aim of this qualitative study was to gain a better understanding of how British South Asian women cope with breast cancer. The NICE (2004) Guidance suggests that appropriate psychological support should be available for all patients through all stages of their treatment from diagnosis to end-of-life. A literature review indicated a paucity of UK based studies on which to base practice. In order to understand the coping experience of this group, ten female South Asian patients being treated for breast cancer were recruited for in-depth semi-structured interviews, which were recorded and transcribed. Data were analysed using constructivist grounded theory to produce a model conceptualising the resources or processes that this group used in order to cope with breast cancer. Analysis elucidated 'Strength through Connection' as the core category, and four main categories: a) Being in mind, b) Wearing a positive cap, c) Preserving relational identity, and d) Realigning values. Facets of the extant coping literature support these findings but much of this research is not from an ethno-cultural perspective. The pattern of coping found in this study can be viewed holistically within a cultural framework and interpreted as predominantly collectivist coping, thereby highlighting the significance of connectedness. Clinicians are encouraged to be better informed regarding cultural differences and preferences in coping, and recommendations are made for counselling psychology practice. The need for further research to meet the NICE (2004) Guidance is highlighted.
APA, Harvard, Vancouver, ISO, and other styles
8

Scullard, Nicole. "Subjective lived experiences of women with early stage breast cancer in Cape Town." University of the Western Cape, 2015. http://hdl.handle.net/11394/5081.

Full text
Abstract:
Magister Artium - MA
Breast cancer is a common cause of death among women worldwide. It has long been recognized as a major public health burden in high-income countries, however, the majority of cases are said to occur in low and middle-income countries, such as in South Africa. A breast cancer diagnosis and treatment heralds a series of frightening events and can be a traumatic experience. The manner in which women perceive and cope with their illness is predictive of emotional and physical health outcomes. It is thus imperative to explore the experiences of South African women, whose voices may have been silenced in the past. The purpose of my study was to explore the subjective lived experiences of women with early stage breast cancer undergoing treatment. The objectives of the study were to; explore the emotional experiences of women with early stage breast cancer undergoing treatment and secondly to explore how women perceive their bodies through their experience of early stage breast cancer while undergoing treatment. Phenomenology was used as the theoretical position conceptualising the study as well as the research design. This research study adopted a qualitative approach utilising in-depth face to face semi-structures interviews for collecting data. The participants were selected through purposive sampling and comprised six women aged between 30 and 40 who are undergoing treatment for early stage breast cancer. The data was analysed using interpretative phenomenological analysis. Emotions experienced were characterised by the shock of the diagnosis due to factors such as lack of family history and age. Participants reported positive changes and viewpoints which they gained through their breast cancer journey. Emotions were heightened during treatment due to the physical change experienced and the effects this had on family members and the general public. Furthermore, results indicated that participants, even though they discovered a new found love for life and for their wellbeing, neglected their emotional needs in order to protect family members. An additional reason for this neglect centered on the lack of understanding other individuals may have regarding the experiences of participants. Recommendations involves the encouragement of accessing counselling services and that interventions tailored to the needs of each patient especially according to age. All ethical considerations as stipulated by the University of the Western Cape were adhered to.
APA, Harvard, Vancouver, ISO, and other styles
9

Winchester, Carolyn Margaret. "Anti-p53 and c-erbB2 as prognostic markers in South African breast cancer patients." Thesis, Cape Technikon, 2000. http://hdl.handle.net/20.500.11838/1518.

Full text
Abstract:
Thesis (DTech(Biomedical Technology))--Cape Technikon, Cape Town, 2000
The diagnosis of breast cancer is not possible using currently available serological detection of cancer markers as these lack adequate sensitivity or specificity. This study investigates the prevalence and significance of anti-p53 antibody and c-erbB-2 protein in the post-surgical sera of South African breast cancer patients and correlates these features with the clinicopathological characteristics of breast cancer. Further, this study investigates the possibilityofimproving prognostic sensitivityby combining the two subject markers to monitor each patient. Further, this study will provide the opportunity to investigate lNhether only certain types of breast cancer can elicit an immunological response and at what stage and grade of tumour antibodies are present in the postoperative serum. The study also establishes a foundation for determining in South Africa lNhether there is a genetic influence in the response to p53 mutation and INhther this response is higher in the indigenous African women compared to other South African women. The purpose of the study is to determine if the resulting findings can be used to enhance our ability to diagnose breast cancer and to identify node-negative breast cancer patients at high risk for early disease recurrence and or death, for 1Nh0m adjuvant therapy is unequivocally justified. The study accrued 92 South African breast cancer patients who were essentially women of colour 62 [67%] indigenous African women and 20 [22%] Caucasian of Indian descent, 6 [6%J of mixed [ColouredJ background and only 4 [4%J Caucasian of White descent. A predominantly indigenous African populationwas chosen becausethey are the group most likely to benefitfrom an easily repeatable, affordable serological cancer marker.
APA, Harvard, Vancouver, ISO, and other styles
10

Ng'ang'a, Mukuhi. "Delay in provision of breast cancer care in patients seen at a district hospital diagnostic breast unit in South Africa." Master's thesis, University of Cape Town, 2018. http://hdl.handle.net/11427/28069.

Full text
Abstract:
Background: There is evidence to show that delays in breast cancer management are detrimental to patient outcome. The aim of this study was to determine time trends and causes of delay in a newly established diagnostic breast clinic based at a district hospital in South Africa. Method: All patients who presented to Mitchells Plain District Hospital Breast Clinic from January to December 2015 and had a diagnosis of breast cancer were included in this study. The intervals between the time she first noted her symptoms to initial contact with a health professional and delivery of definitive therapy was documented. Patient delay referred to the interval from when the patient first noted her symptoms to her initial contact with a health care provider. Provider delay referred to the interval between the first hospital visit and onset of therapy. Result: A total of 33 patients were enrolled in this study. The median overall total delay (time lapse between the moment the patient first noticed her symptoms to time definitive anti-cancer treatment was started) was 157days, (range 29 to 839 days). Median patient delay (time lapse between the moment the patient first noticed her symptoms and the visit to a health professional) was 56 days, (range 7 to 730 days). Median overall provider delay (time lapse between the patients' first encounter with a clinician to time definitive anti-cancer treatment was started) was 84 days, (range 22 to 338 days). Median Referral delay was 11 days (range 4 to 39 days). Median Diagnostic delay was 15 days (range 9 to 135 days) and median treatment delay was 45 days (range 5 to 246 days). Conclusion: The median overall total delay for patients diagnosed with breast cancer at Mitchells Plain District Hospital does not compares well with institutions in developed nations but it is similar to studies done in developing nations. The largest contributor to this delay was patient delay. The main contributors to provider delay was related to diagnosis (almost exclusively related to tissue diagnosis) and treatment (mainly patients who received surgery as their first definitive therapy).
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Breast Cancer South Australia"

1

Kricker, Anne. Breast cancer in Australia. Sydney: Alpha Biomedical Communications, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Australian Institute of Health and Welfare. Breast cancer in Australia: An overview, 2009. Canberra: Australian Institute of Health and Welfare, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Welfare, Australian Institute of Health and. Breast cancer in Australia: An overview, 2009. Canberra: Australian Institute of Health and Welfare, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Western Australia. Working Party on Screening Mammography. Report to the Minister for Health for Western Australia from the Working Party on Screening Mammography. Perth: Health Dept. of Western Australia, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Australia, BreastScreen. BreastScreen Australia monitoring report / the Australian Institute of Health Welfare and the Australian Government Department of Health and Aging for the BreastScreen Australia Program. Canberra: Australian Institute of Health and Welfare, c2003., 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Australian Institute of Health and Welfare. Cancer and Screening Unit. Risk of invasive breast cancer in women diagnosed with ductal carcinoma in situ in Australia between 1995 and 2005. Canberra: Australian lInstitute of Health and Welfare, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Young, Deidra J. A report on women attending the Screening Mammography Pilot Programme in Western Australia: A compilation of eight client satisfaction surveys undertaken in Western Australia between May,1989 and May,1990. Subiaco, W.A: Women's Cancer Prevention Unit, Disease Control Branch, Health Dept. of Western Australia, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

When hope whispers. Auckland Park, South Africa: Jacana, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Where the river ends. [London]: Ebury, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nielsen, Jerri. Ice bound: A doctor's incredible battle for survival at the South Pole. New York: Hyperion Books, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Breast Cancer South Australia"

1

Spillane, Andrew J., and Meagan E. Brennan. "Breast Carcinoma Surveillance Counterpoint: Australia." In Patient Surveillance After Cancer Treatment, 285–91. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-60327-969-7_56.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Agostino, Catarina, and Renee Middlemost. "The Impact of Femvertising on Pink Breast Cancer Products in Australia." In Palgrave Studies in (Re)Presenting Gender, 115–40. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-99154-8_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Smit, Anri. "Exploring the Use of Body Mapping for Socially Inclusive Storytelling Among South African Women Living with Recurrent Breast Cancer." In Handbook of Social Inclusion, 1–20. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-48277-0_64-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Smit, Anri. "Exploring the Use of Body Mapping for Socially Inclusive Storytelling Among South African Women Living with Recurrent Breast Cancer." In Handbook of Social Inclusion, 1193–211. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-89594-5_64.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Cancer Council South Australia." In The Grants Register 2020, 230. London: Palgrave Macmillan UK, 2019. http://dx.doi.org/10.1057/978-1-349-95943-3_227.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Cancer Council South Australia." In The Grants Register 2021, 247–48. London: Palgrave Macmillan UK, 2020. http://dx.doi.org/10.1057/978-1-349-95988-4_230.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"Cancer Council South Australia." In The Grants Register 2022, 269. London: Palgrave Macmillan UK, 2021. http://dx.doi.org/10.1057/978-1-349-96042-2_9820.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Cancer Council South Australia." In The Grants Register 2023, 283. London: Palgrave Macmillan UK, 2022. http://dx.doi.org/10.1057/978-1-349-96053-8_9720.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"The Cancer Council South Australia." In The Grants Register 2018, 223–24. London: Palgrave Macmillan UK, 2018. http://dx.doi.org/10.1007/978-1-349-94186-5_286.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"The Cancer Council South Australia." In The Grants Register 2019, 218–19. London: Palgrave Macmillan UK, 2018. http://dx.doi.org/10.1007/978-1-349-95810-8_288.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Breast Cancer South Australia"

1

Jacklyn, Gemma, Kevin McGeechan, Les Irwig, Nehmat Houssami, Stephen Morrell, Katy Bell, and Alexandra Barratt. "48 Trends in stage-specific breast cancer incidence in new south wales, australia: insights from 25 years of screening mammography." In Preventing Overdiagnosis, Abstracts, August 2018, Copenhagen. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/bmjebm-2018-111070.48.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Adams, Swann Arp, Samantha C. Truman, Oluwole Babatunde, Tisha M. Felder, Jan M. Eberth, Sue P. Heiney, Christian R. Alvarado, and James R. Hebert. "Abstract B008: South Carolina's National Breast and Cervical Cancer Early Detection Program narrows the gap in South Carolina breast cancer disparities." In Abstracts: Eleventh AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; November 2-5, 2018; New Orleans, LA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7755.disp18-b008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Farber, Rachel, Alexandra Barratt, Nehmat Houssami, Kevin McGeechan, and Katy Bell. "81 Has the transition to digital mammography in breast cancer screening resulted in real benefits?" In Preventing Overdiagnosis Abstracts, December 2019, Sydney, Australia. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/bmjebm-2019-pod.93.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Moodley, Jennifer. "Abstract IA33: Pathways to breast cancer care in South Africa." In Abstracts: AACR International Conference: New Frontiers in Cancer Research; January 18-22, 2017; Cape Town, South Africa. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.newfront17-ia33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lombard, Janine M., Nicholas Zdenkowski, Kathy Wells, Nicca Grant, Linda Reaby, John F. Forbes, and Jacquie Chirgwin. "Abstract P1-12-05: Aromatase inhibitor induced musculoskeletal syndrome (AIMSS) in Australian women with early breast cancer: An Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) survey of members of the Breast Cancer Network Australia (BCNA)." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p1-12-05.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lupicki, Kamil, Selene Elifio-Esposito, Aline S. Fonseca, Akanksha Mahajan, Silma R. Pereira, B. Langa, Dhirendra Govender, et al. "Abstract A14: Copy number profiling in South African breast cancer patients." In Abstracts: AACR International Conference: New Frontiers in Cancer Research; January 18-22, 2017; Cape Town, South Africa. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.newfront17-a14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rahim, Hindun. "Risk Factors of Breast Cancer in South-East Asia: A Systematic Review." In The 6th International Conference on Public Health 2019. Masters Program in Public Health, Graduate School, Universitas Sebelas Maret, 2019. http://dx.doi.org/10.26911/the6thicph.01.21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Burton, Robert, and Christopher Stephenson. "82 Effect of a quarter century of adjuvant therapy and mammographic screening on breast cancer mortality in the state of victoria, australia." In Preventing Overdiagnosis Abstracts, December 2019, Sydney, Australia. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/bmjebm-2019-pod.94.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nair-Shalliker, Visalini, David P. Smith, Sam Egger, Ann Marie Hughes, Mark Clements, Anne Kricker, and Bruce K. Armstrong. "Abstract 5482: Sun exposure and prostate cancer risk in New South Wales, Australia: A case control study." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-5482.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Caleffi, M., RA Ribeiro, A. Bedin, JV Butzke, D. Duarte, G. Skonieski, P. Kivitz, and B. Weber. "Adherence to mammographic screening in a centralized breast health program in South Brazil: preliminary results." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-5092.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Breast Cancer South Australia"

1

Rankin, Nicole, Deborah McGregor, Candice Donnelly, Bethany Van Dort, Richard De Abreu Lourenco, Anne Cust, and Emily Stone. Lung cancer screening using low-dose computed tomography for high risk populations: Investigating effectiveness and screening program implementation considerations: An Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the Cancer Institute NSW. The Sax Institute, October 2019. http://dx.doi.org/10.57022/clzt5093.

Full text
Abstract:
Background Lung cancer is the number one cause of cancer death worldwide.(1) It is the fifth most commonly diagnosed cancer in Australia (12,741 cases diagnosed in 2018) and the leading cause of cancer death.(2) The number of years of potential life lost to lung cancer in Australia is estimated to be 58,450, similar to that of colorectal and breast cancer combined.(3) While tobacco control strategies are most effective for disease prevention in the general population, early detection via low dose computed tomography (LDCT) screening in high-risk populations is a viable option for detecting asymptomatic disease in current (13%) and former (24%) Australian smokers.(4) The purpose of this Evidence Check review is to identify and analyse existing and emerging evidence for LDCT lung cancer screening in high-risk individuals to guide future program and policy planning. Evidence Check questions This review aimed to address the following questions: 1. What is the evidence for the effectiveness of lung cancer screening for higher-risk individuals? 2. What is the evidence of potential harms from lung cancer screening for higher-risk individuals? 3. What are the main components of recent major lung cancer screening programs or trials? 4. What is the cost-effectiveness of lung cancer screening programs (include studies of cost–utility)? Summary of methods The authors searched the peer-reviewed literature across three databases (MEDLINE, PsycINFO and Embase) for existing systematic reviews and original studies published between 1 January 2009 and 8 August 2019. Fifteen systematic reviews (of which 8 were contemporary) and 64 original publications met the inclusion criteria set across the four questions. Key findings Question 1: What is the evidence for the effectiveness of lung cancer screening for higher-risk individuals? There is sufficient evidence from systematic reviews and meta-analyses of combined (pooled) data from screening trials (of high-risk individuals) to indicate that LDCT examination is clinically effective in reducing lung cancer mortality. In 2011, the landmark National Lung Cancer Screening Trial (NLST, a large-scale randomised controlled trial [RCT] conducted in the US) reported a 20% (95% CI 6.8% – 26.7%; P=0.004) relative reduction in mortality among long-term heavy smokers over three rounds of annual screening. High-risk eligibility criteria was defined as people aged 55–74 years with a smoking history of ≥30 pack-years (years in which a smoker has consumed 20-plus cigarettes each day) and, for former smokers, ≥30 pack-years and have quit within the past 15 years.(5) All-cause mortality was reduced by 6.7% (95% CI, 1.2% – 13.6%; P=0.02). Initial data from the second landmark RCT, the NEderlands-Leuvens Longkanker Screenings ONderzoek (known as the NELSON trial), have found an even greater reduction of 26% (95% CI, 9% – 41%) in lung cancer mortality, with full trial results yet to be published.(6, 7) Pooled analyses, including several smaller-scale European LDCT screening trials insufficiently powered in their own right, collectively demonstrate a statistically significant reduction in lung cancer mortality (RR 0.82, 95% CI 0.73–0.91).(8) Despite the reduction in all-cause mortality found in the NLST, pooled analyses of seven trials found no statistically significant difference in all-cause mortality (RR 0.95, 95% CI 0.90–1.00).(8) However, cancer-specific mortality is currently the most relevant outcome in cancer screening trials. These seven trials demonstrated a significantly greater proportion of early stage cancers in LDCT groups compared with controls (RR 2.08, 95% CI 1.43–3.03). Thus, when considering results across mortality outcomes and early stage cancers diagnosed, LDCT screening is considered to be clinically effective. Question 2: What is the evidence of potential harms from lung cancer screening for higher-risk individuals? The harms of LDCT lung cancer screening include false positive tests and the consequences of unnecessary invasive follow-up procedures for conditions that are eventually diagnosed as benign. While LDCT screening leads to an increased frequency of invasive procedures, it does not result in greater mortality soon after an invasive procedure (in trial settings when compared with the control arm).(8) Overdiagnosis, exposure to radiation, psychological distress and an impact on quality of life are other known harms. Systematic review evidence indicates the benefits of LDCT screening are likely to outweigh the harms. The potential harms are likely to be reduced as refinements are made to LDCT screening protocols through: i) the application of risk predication models (e.g. the PLCOm2012), which enable a more accurate selection of the high-risk population through the use of specific criteria (beyond age and smoking history); ii) the use of nodule management algorithms (e.g. Lung-RADS, PanCan), which assist in the diagnostic evaluation of screen-detected nodules and cancers (e.g. more precise volumetric assessment of nodules); and, iii) more judicious selection of patients for invasive procedures. Recent evidence suggests a positive LDCT result may transiently increase psychological distress but does not have long-term adverse effects on psychological distress or health-related quality of life (HRQoL). With regards to smoking cessation, there is no evidence to suggest screening participation invokes a false sense of assurance in smokers, nor a reduction in motivation to quit. The NELSON and Danish trials found no difference in smoking cessation rates between LDCT screening and control groups. Higher net cessation rates, compared with general population, suggest those who participate in screening trials may already be motivated to quit. Question 3: What are the main components of recent major lung cancer screening programs or trials? There are no systematic reviews that capture the main components of recent major lung cancer screening trials and programs. We extracted evidence from original studies and clinical guidance documents and organised this into key groups to form a concise set of components for potential implementation of a national lung cancer screening program in Australia: 1. Identifying the high-risk population: recruitment, eligibility, selection and referral 2. Educating the public, people at high risk and healthcare providers; this includes creating awareness of lung cancer, the benefits and harms of LDCT screening, and shared decision-making 3. Components necessary for health services to deliver a screening program: a. Planning phase: e.g. human resources to coordinate the program, electronic data systems that integrate medical records information and link to an established national registry b. Implementation phase: e.g. human and technological resources required to conduct LDCT examinations, interpretation of reports and communication of results to participants c. Monitoring and evaluation phase: e.g. monitoring outcomes across patients, radiological reporting, compliance with established standards and a quality assurance program 4. Data reporting and research, e.g. audit and feedback to multidisciplinary teams, reporting outcomes to enhance international research into LDCT screening 5. Incorporation of smoking cessation interventions, e.g. specific programs designed for LDCT screening or referral to existing community or hospital-based services that deliver cessation interventions. Most original studies are single-institution evaluations that contain descriptive data about the processes required to establish and implement a high-risk population-based screening program. Across all studies there is a consistent message as to the challenges and complexities of establishing LDCT screening programs to attract people at high risk who will receive the greatest benefits from participation. With regards to smoking cessation, evidence from one systematic review indicates the optimal strategy for incorporating smoking cessation interventions into a LDCT screening program is unclear. There is widespread agreement that LDCT screening attendance presents a ‘teachable moment’ for cessation advice, especially among those people who receive a positive scan result. Smoking cessation is an area of significant research investment; for instance, eight US-based clinical trials are now underway that aim to address how best to design and deliver cessation programs within large-scale LDCT screening programs.(9) Question 4: What is the cost-effectiveness of lung cancer screening programs (include studies of cost–utility)? Assessing the value or cost-effectiveness of LDCT screening involves a complex interplay of factors including data on effectiveness and costs, and institutional context. A key input is data about the effectiveness of potential and current screening programs with respect to case detection, and the likely outcomes of treating those cases sooner (in the presence of LDCT screening) as opposed to later (in the absence of LDCT screening). Evidence about the cost-effectiveness of LDCT screening programs has been summarised in two systematic reviews. We identified a further 13 studies—five modelling studies, one discrete choice experiment and seven articles—that used a variety of methods to assess cost-effectiveness. Three modelling studies indicated LDCT screening was cost-effective in the settings of the US and Europe. Two studies—one from Australia and one from New Zealand—reported LDCT screening would not be cost-effective using NLST-like protocols. We anticipate that, following the full publication of the NELSON trial, cost-effectiveness studies will likely be updated with new data that reduce uncertainty about factors that influence modelling outcomes, including the findings of indeterminate nodules. Gaps in the evidence There is a large and accessible body of evidence as to the effectiveness (Q1) and harms (Q2) of LDCT screening for lung cancer. Nevertheless, there are significant gaps in the evidence about the program components that are required to implement an effective LDCT screening program (Q3). Questions about LDCT screening acceptability and feasibility were not explicitly included in the scope. However, as the evidence is based primarily on US programs and UK pilot studies, the relevance to the local setting requires careful consideration. The Queensland Lung Cancer Screening Study provides feasibility data about clinical aspects of LDCT screening but little about program design. The International Lung Screening Trial is still in the recruitment phase and findings are not yet available for inclusion in this Evidence Check. The Australian Population Based Screening Framework was developed to “inform decision-makers on the key issues to be considered when assessing potential screening programs in Australia”.(10) As the Framework is specific to population-based, rather than high-risk, screening programs, there is a lack of clarity about transferability of criteria. However, the Framework criteria do stipulate that a screening program must be acceptable to “important subgroups such as target participants who are from culturally and linguistically diverse backgrounds, Aboriginal and Torres Strait Islander people, people from disadvantaged groups and people with a disability”.(10) An extensive search of the literature highlighted that there is very little information about the acceptability of LDCT screening to these population groups in Australia. Yet they are part of the high-risk population.(10) There are also considerable gaps in the evidence about the cost-effectiveness of LDCT screening in different settings, including Australia. The evidence base in this area is rapidly evolving and is likely to include new data from the NELSON trial and incorporate data about the costs of targeted- and immuno-therapies as these treatments become more widely available in Australia.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Breast Cancer South Australia' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography